Skip to main content
. 2022 Dec 15;27(50):2200896. doi: 10.2807/1560-7917.ES.2022.27.50.2200896

Table 1. Epidemiological characteristics of patients with CPE, CPPA, CRAB, MRSA and multiple MDRO originating from Ukraine, the Netherlands, sampled 1 March–31 August 2022 (n = 58).

Characteristic CPEa (n = 39) CPPAb (n = 12) CRABb (n = 3) MRSAb (n = 13) Multiple MDROa,b,c (n = 11)
n n n n n
Median age in years (range) 34 (0–86) 31 (2–66) 45 (36–66) 27 (0–70) 28 (16–66)
Male 26 11 2 12 9
Female 13 1 1 1 2
Type of material
Swabs from nose/throat/rectum/perineum 26 6 0 11 5
Wound/pus 10 6 3 2 5
Urine 3 0 0 0 1
Additional metadata available 39 7 0d 12 11
Reason for culturing
Diagnostic/clinical indication 5 4 0 3e 2
Screening for MDRO, contact tracing or belongs to risk group 32 3 0 10e 8
Other/unknown 2 NC NC NC 1
Sampling location
Outpatient clinic 11 0 0 4 1
Inpatient ward 24 7 0 6 9
Intensive care unit 3 0 0 2 0
Unknown 1 0 0 0 1
Invasive medical procedure/diagnostics
Yes 22 1 0 NC 11
No 1 3 0 NC 0
Unknown 16 3 0 NC 0
Risk factor
Hospitalisation abroad > 24 h during the previous 2 months 21 6 0 2 10

CPE: carbapenemase-producing Enterobacterales; CPPA: carbapenemase-producing Pseudomonas aeruginosa; CRAB: carbapenem-resistant Acinetobacter baumannii; MDRO: multidrug-resistant organism; MRSA: meticillin-resistant Staphylococcus aureus; NC: not collected.

a Based on the notifications in the national mandatory notification system.

b Based on the metadata entered in the database of the Dutch national surveillance.

c These patients are also taken into account in columns ‘CPE’, ‘CPPA’ and ‘MRSA’, where applicable.

d For CRAB, additional epidemiological data were not available because this pilot surveillance started only in August 2022.

e One questionnaire was incomplete and only this question was available and therefore the denominator is 13 for this item.